Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$327.16 USD

327.16
809,371

+5.25 (1.63%)

Updated Nov 8, 2024 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

by Kinjel Shah

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis

by Zacks Equity Research

AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Roche & Honeywell International

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Roche Holding AG (RHHBY) and Honeywell International Inc. (HON).

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

by Zacks Equity Research

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Hubbell, Adobe, Nikola in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?

by Zacks Equity Research

AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Santanu Roy headshot

Beat the Market the Zacks Way: Caterpillar, Amgen, Broadridge Financial Solutions in Focus

by Santanu Roy

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

by Zacks Equity Research

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Company News for Aug 7, 2023

by Zacks Equity Research

Companies in The News Are: PPL,PAA,TU,AMGN

Ligand (LGND) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.

Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.

Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amgen (AMGN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 75% and 6.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $235.42, moving +0.26% from the previous trading session.

Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing

by Zacks Equity Research

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

by Zacks Equity Research

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.